Clinical trials: MS
Multiple Sclerosis
Pharmacodynamic Study to Better Understand the Therapeutic Response and Immunomodulatory Effects of Avonex in Multiple Sclerosis (MS) Patients and Healthy Volunteers
This study will look at differences in bioanalytical measures among different groups of MS patients and Healthy Volunteers, when administered interferon beta-1a.
- Trial name
- NCT00913666
- Testing
- Interferon beta-1a (Avonex)
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Patient Centered Outcomes Analysis for MS Using a Mobile Application
Multiple Sclerosis (MS) is a demyelinating disease of the central nervous system (CNS) that can impact all aspects of nervous system function.
- Trial name
- NCT04281160
- Testing
- BeCare Mobile App
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- BeCare Link LLC
Healthy
Safety, Pharmacokinetics and Pharmacodynamics After Multiple Oral Doses of BIBR 1048 MS Capsule in Healthy Japanese Male Subjects
To investigate safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of multiple doses (150 mg b.i.d., 7 days)
- Trial name
- NCT02171000
- Testing
- BIBR 1048 MS
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BIBR 963 ZW After 50 mg of BIBR 1048 MS With and Without of Pantoprazole in Healthy Subjects
To assess the amount of BIBR 953 ZW in urine of 50 mg of BIBR 1048 bid over three days each administered as four experimental capsule formulations relative to drinking solution with and without coadministration of 40 mg…
- Trial name
- NCT02170896
- Testing
- BIBR 1048 MS Capsule A, BIBR 1048 MS Capsule B, BIBR 1048 MS Capsule C
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BIBR 953 ZW After Administration of BIBR 1048 MS in Healthy Subjects
Study to assess the amount of BIBR 953 ZW in urine and concentrations in plasma after administration of 50 mg of BIBR 1048 bid over three days each administered as two experimental formulations relative to drinking solution with…
- Trial name
- NCT02170623
- Testing
- BIBR 1048 MS Capsule I, BIBR 1048 MS Capsule K, Pantoprazole
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent
This study will utilize a prospective, observational, exposure cohort design to examine pregnancy and infant outcomes in women and infants who are exposed to siponimod during pregnancy to treat MS.
- Trial name
- NCT04933552
- Testing
- Siponimod
- Where
- United States
- Volunteers
- 867 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD)
Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers
This is a Phase 1/2 study to evaluate the safety and tolerability of 18F-OP-801 in subjects with ALS, AD, MS, PD and age-matched HVs.
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Parkinson Disease (PD), Alzheimer Disease (AD), Multiple Sclerosis (MS)
- Trial name
- NCT05395624
- Testing
- 18F-OP-801
- Where
- 3 sites in United States
- Volunteers
- 65 people, healthy volunteers welcome
- Sponsor
- Ashvattha Therapeutics, Inc.
Healthy
Safety, Pharmacokinetics and Pharmacodynamics of BIBR 1048 MS Capsule in Healthy Male Subjects of Japanese and Caucasian Origin
Study to investigate and compare safety, pharmacokinetics and pharmacodynamics of BIBR 1048 MS following oral administration of single (150 mg, 220 mg and 300 mg) and multiple (150 mg and 220 mg q.d.
- Trial name
- NCT02170909
- Testing
- BIBR 1048 MS low dose, BIBR 1048 MS medium dose, BIBR 1048 MS high dose
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BIBR 1048 MS With and Without Pantoprazole Under Influence of Food in Healthy Subjects
To assess the extent of absorption of 150 mg of BIBR 1048 administered as capsule formulation with and without coadministration of 40 mg Pantoprazole and to assess the effect of food on rate and extent of absorption.
- Trial name
- NCT02170610
- Testing
- BIBR 1048 MS, Pantoprazole
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BIBR 953 ZW After Oral Administration of BIBR 1048 MS in Healthy Subjects
Study to assess the amount of BIBR 953 ZW in urine after administration of 50 mg BIBR 1048 bid over three days each administered as four experimental formulations relative to drinking solution with and without coadministration of…
- Trial name
- NCT02170636
- Testing
- BIBR 1048 MS Capsule E, BIBR 1048 MS Capsule F, BIBR 1048 MS Capsule G
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis (MS)
A Study to Evaluate the Safety, Tolerability, Kinetics, Biodistribution and Repeatability of 11C-BMS-986196 After Intravenous (IV) Administration in Healthy Participants and After Repeat IV Administration in Participants With Multiple Sclerosis
The purpose of this study is to evaluate the safety, tolerability, kinetics, biodistribution and central nervous system signal of 11C-BMS-986196 after intravenous (IV) administration in healthy participants and after repeat IV…
- Trial name
- NCT05064436
- Testing
- 11C-BMS-986196
- Where
- 2 sites in United States, United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Multiple Oral Doses of BIBR 1048 MS Solution in Healthy Volunteers
To assess safety, pharmacokinetics and the effect of BIBR 1048 MS on coagulation parameters.
- Trial name
- NCT02170831
- Testing
- BIBR 1048 MS low, BIBR 1048 MS medium 1, BIBR 1048 MS medium 2
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy Volunteer
MS PATHS Normative Sub-Study
The primary objective of this study is to determine the normative range of brain volume and brain volume change in healthy control (HC) participants whose age, race, and gender distribution is approximately matched to the age…
- Trial name
- NCT02996084
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 246 people, healthy volunteers welcome
- Sponsor
- Biogen
Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis
PET Study of PIPE-791 in Healthy Volunteers and Volunteers With PrMS and IPF
This is a study of PIPE-791, an investigational study drug to treat progressive multiple sclerosis (MS) and idiopathic pulmonary fibrosis (IPF).
- Conditions
- Idiopathic Pulmonary Fibrosis (IPF), Idiopathic Pulmonary Fibrosis, Multiple Sclerosis, Multiple Sclerosis, MS
- Trial name
- NCT06683612
- Testing
- PIPE-791
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Contineum Therapeutics
Multiple Sclerosis (MS)
Avonex®: Safety, Blood Levels and Effects
The primary objective was to determine the tolerability of a new inhaled formulation of interferon beta-1a when given as a single dose, when given once per week for 4 weeks, and compared with standard intramuscular (IM) AVONEX®…
- Trial name
- C-851 (NCT01863069)
- Testing
- Interferon beta 1a, (IM) AVONEX®
- Where
- United Kingdom
- Volunteers
- 77 people, healthy volunteers welcome
- Sponsor
- Trio Medicines Ltd.
Healthy Volunteers, Multiple Sclerosis
Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in Healthy Subjects and Multiple Sclerosis(MS) Patients
In this first in human study the aim is to assess the safety, pharmacokinetics and pharmacodynamics of 2B3-201 in a randomized, first in human, double-blind, placebo- and active comparator- controlled 3-way crossover study in 18…
- Trial name
- NCT02048358
- Testing
- 2B3-201, Methylprednisolone hemisuccinate
- Where
- 2 sites in Netherlands
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BBB-Therapeutics B.V.
Multiple Sclerosis
Characterization of White Blood Cells Sub-populations From Multiple Sclerosis Patients.
Multiple sclerosis (MS) is a chronic progressive neurological autoimmune disease, that gradually affects patient's quality of life. There are about 2.5 millions patients world wide, with an increasing cost Burdon.
- Trial name
- NCT03486665
- Testing
- Blood Sampling, CSF Sampling
- Where
- Israel
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Bioimmunate
Healthy
Bioavailability of BIBR 1048 MS Tablets in Healthy Subjects With or Without Food
Comparative pharmacokinetics of BIBR 1048 MS solution and tablet with or without food
- Trial name
- NCT02170922
- Testing
- BIBR 1048 MS tablet, BIBR 1048 MS solution
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Healthy
Bioavailability of BIBR 953 ZW After Dose of BIBR 1048 MS
To assess the extent of absorption of 12.5, 50 and 200 mg of BIBR 1048 MS with and without coadministration of 150 mg ranitidine.
- Trial name
- NCT02170792
- Testing
- BIBR 1048 MS, Ranitidine
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Multiple Sclerosis
Monitoring of Multiple Sclerosis (MS) Participants With the Use of Digital Technology (Smartphones and Smartwatches) - A Feasibility Study
This prospective pilot study will assess the feasibility of remote participant monitoring using digital technology in participants with MS and healthy controls.
- Trial name
- NCT02952911
- Testing
- Smartphone and Smartwatch
- Where
- 2 sites in United States, Spain
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Hoffmann-La Roche